LinkedIn·Wednesday, 19 August 2026·7d ago

When I started ImmuneWatch, I was still very much a researcher. Head down in the analysis. Trying to make the technology better, adding…

Sander Wuyts

Extract real value out of TCR repertoires | 🔎 CEO ImmuneWatch

When I started ImmuneWatch, I was still very much a researcher. Head down in the analysis. Trying to make the technology better, adding training datasets one at a time. That is not really my day anymore. These days I spend most of my time on two things: the team, and the ImmuneWatch brand and business development. My calendar looks less like a lab notebook and more like a mix of everything at once (which is a good thing 😊 ) Today for example: 1️⃣ This morning I recorded a podcast episode with a customer we worked with. I thought it was really exciting to talk with a cancer vaccine company CSO and how TCR seq helped them better understand their clinical data. -> The kind of thing that reminds you why this work matters. 2️⃣ Straight after, a discovery call with a potential new customer, figuring out together whether TCR sequencing actually fits their research question. -> Always nice to meet new people that are passionate about what they do 3️⃣ Then a standup with the team, going through what everyone is working on and clearing whatever is blocking them. 4️⃣ This afternoon: building a new outreach campaign. Four completely different hats in one day. I'll admit that I miss being deep in the data sometimes. But watching the team run with the science, while I focus on getting ImmuneWatch in front of the right people, has its own kind of reward.